Rivaroxaban Assay
Test Mnemonic
RVXBAN
CPT Codes
- 80299 - QTY (1)
LOINC ®
68979-4
Aliases
- Xarelto
Performing Laboratory
Cleveland Clinic Laboratories
FDA Category
Research Use Only
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.7 mL | Plasma | Sodium citrate (Lt. Blue) | Frozen |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.5 mL | Minimum is 0.5 mL plasma |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | 4 hours |
| Refrigerated | Unacceptable |
| Frozen | 4 weeks |
Days Performed
Sun - Sat
Turnaround Time
4 hours
Methodology
| Name | Description |
|---|---|
| Chromogenic |
Reference Range
| Rivaroxaban | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Dosage: 20 mg qD; Peak: 215 (22 - 535) ug/L | Dosage: 20 mg qD; Trough: 32 (6 - 239) ug/L | Dosage: 15 mg qD; Peak: 215 (22 - 535) ug/L | Dosage: 15 mg qD; Trough: 32 (6 - 239) ug/L | Dosage: 10 mg qD; Peak: 101 (7 - 273) ug/L | Dosage: 10 mg qD; Trough: 14 (4 - 51) ug/L |
Special Info
Peak: 2 - 4 hours after dose; Trough: 24 hours after dose
Clinical Info
Rivaroxaban (Bayer Pharma AG, Germany) is a highly selective direct factor Xa inhibitor with oral bioavailability. Rivaroxaban binds directly to the catalytic site of the serine protease factor Xa independently of antithrombin, and inhibits both free and prothrombinase-bound factor Xa. It is indicated to prevent and treat thromboembolic disorders such as ischemic stroke, systemic embolism or nonvalvular atrial fibrillation. It also reduces the risk of recurrence of deep vein thrombosis or pulmonary embolism in patients receiving orthopedic surgery. Rivaroxaban can provide more consistent and predictable anticoagulation than other anticoagulants such as warfarin. Routine laboratory monitoring for rivaroxaban is not necessary. However, rivaroxaban measurement will be necessary in patients suspicious of poor compliance or failure of therapy, patients who require potential dose adjustment or patients with hepatic/renal dysfunction. As a direct factor Xa inhibitor, clotting times of coagulation tests downstream from factor Xa including PT and APTT will be prolonged. Rivaroxaban will be measured by chromogenic anti-Xa assay using specific STA-Rivaroxaban in STA-R Evolution coagulometer.